These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

820 related items for PubMed ID: 17265527

  • 1. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N, Klotz L, Crook J, Goldenberg SL.
    Cancer; 2007 Mar 01; 109(5):858-67. PubMed ID: 17265527
    [Abstract] [Full Text] [Related]

  • 2. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
    Bruchovsky N, Klotz L, Crook J, Malone S, Ludgate C, Morris WJ, Gleave ME, Goldenberg SL.
    Cancer; 2006 Jul 15; 107(2):389-95. PubMed ID: 16783817
    [Abstract] [Full Text] [Related]

  • 3. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 4. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug 15; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S, Lawrentschuk N, Grills RJ, Neerhut G.
    J Urol; 2005 Jul 15; 174(1):140-2. PubMed ID: 15947599
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer.
    Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg SL.
    Clin Genitourin Cancer; 2008 Mar 15; 6(1):46-52. PubMed ID: 18501083
    [Abstract] [Full Text] [Related]

  • 8. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 15; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.
    Urology; 2008 Jan 15; 71(1):136-40. PubMed ID: 18242382
    [Abstract] [Full Text] [Related]

  • 15. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM, Rose AL, Higano C.
    J Urol; 2003 Nov 15; 170(5):1808-11. PubMed ID: 14532781
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.
    Eur Urol; 2009 Jun 15; 55(6):1269-77. PubMed ID: 19249153
    [Abstract] [Full Text] [Related]

  • 18. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.
    Moul JW.
    Mol Urol; 2000 Jun 15; 4(3):267-71;discussion 273. PubMed ID: 11062383
    [Abstract] [Full Text] [Related]

  • 19. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E, Tekyi-Mensah S, Hart K, Bolton S, Forman J.
    Am J Clin Oncol; 2003 Oct 15; 26(5):e119-23. PubMed ID: 14528085
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.
    BJU Int; 2008 Dec 15; 102(11):1531-8. PubMed ID: 19035858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.